KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Share-based Compensation (2023 - 2025)

Biocryst Pharmaceuticals' Share-based Compensation history spans 9 years, with the latest figure at $23.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 11.5% year-over-year to $23.8 million; the TTM value through Dec 2025 reached $85.1 million, up 30.04%, while the annual FY2025 figure was $85.1 million, 30.04% up from the prior year.
  • Share-based Compensation reached $23.8 million in Q4 2025 per BCRX's latest filing, up from $18.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $23.8 million in Q4 2025 to a low of $12.3 million in Q3 2023.
  • Average Share-based Compensation over 3 years is $17.2 million, with a median of $16.9 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: fell 2.53% in 2024, then soared 61.72% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $16.5 million in 2023, then grew by 29.42% to $21.3 million in 2024, then rose by 11.5% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Share-based Compensation are $23.8 million (Q4 2025), $18.6 million (Q3 2025), and $21.3 million (Q2 2025).